Literature DB >> 25453047

Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease.

David M Schuster1, Cristina Nanni2, Stefano Fanti2, Shuntaro Oka3, Hiroyuki Okudaira3, Yusuke Inoue4, Jens Sörensen5, Rikard Owenius6, Peter Choyke7, Baris Turkbey7, Trond V Bogsrud8, Tore Bach-Gansmo9, Raghuveer K Halkar10, Jonathon A Nye10, Oluwaseun A Odewole10, Bital Savir-Baruch10, Mark M Goodman10.   

Abstract

UNLABELLED: Anti-1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid ((18)F-FACBC) is a synthetic amino acid analog PET radiotracer undergoing clinical trials for the evaluation of prostate and other cancers. We aimed to describe common physiologic uptake patterns, incidental findings, and variants in patients who had undergone (18)F-FACBC PET.
METHODS: Sixteen clinical trials involving 611 (18)F-FACBC studies from 6 centers, which included dosimetry studies on 12 healthy volunteers, were reviewed. Qualitative observations of common physiologic patterns, incidental uptake, and variants that could simulate disease were recorded and compared with similar observations in studies of the healthy volunteers. Quantitative analysis of select data and review of prior published reports and observations were also made.
RESULTS: The liver and pancreas demonstrated the most intense uptake. Moderate salivary and pituitary uptake and variable mild to moderate bowel activity were commonly visualized. Moderate bone marrow and mild muscle activity were present on early images, with marrow activity decreasing and muscle activity increasing with time. Brain and lungs demonstrated activity less than blood pool. Though (18)F-FACBC exhibited little renal excretion or bladder uptake during the clinically useful early imaging time window, mild to moderate activity might accumulate in the bladder and interfere with evaluation of adjacent prostate bed and seminal vesicles in 5%-10% of patients. Uptake might also occur from benign processes such as infection, inflammation, prostatic hyperplasia, and metabolically active benign bone lesions such as osteoid osteoma.
CONCLUSION: Common physiologic uptake patterns were similar to those noted in healthy volunteers. The activity in organs followed the presence of amino acid transport and metabolism described with other amino acid-based PET radiotracers. As with other PET radiotracers such as (18)F-FDG, focal nonphysiologic uptake may represent incidental malignancy. Uptake due to benign etiologies distinct from physiologic background also occurred and could lead to misinterpretations if the reader is unaware of them.
© 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

Entities:  

Keywords:  18F-FACBC; physiologic uptake; positron emission tomography

Mesh:

Substances:

Year:  2014        PMID: 25453047      PMCID: PMC4844004          DOI: 10.2967/jnumed.114.143628

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  34 in total

Review 1.  Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy.

Authors:  Takeo Nakanishi; Ikumi Tamai
Journal:  J Pharm Sci       Date:  2011-05-31       Impact factor: 3.534

2.  FDG-PET: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12       Impact factor: 9.236

3.  Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma.

Authors:  David M Schuster; John R Votaw; Peter T Nieh; Weiping Yu; Jonathon A Nye; Viraj Master; F DuBois Bowman; Muta M Issa; Mark M Goodman
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

Review 4.  Radiolabeled amino acids for oncologic imaging.

Authors:  Chaofeng Huang; Jonathan McConathy
Journal:  J Nucl Med       Date:  2013-05-24       Impact factor: 10.057

Review 5.  Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents.

Authors:  Jonathan McConathy; Weiping Yu; Nachwa Jarkas; Wonewoo Seo; David M Schuster; Mark M Goodman
Journal:  Med Res Rev       Date:  2011-07-26       Impact factor: 12.944

Review 6.  Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond.

Authors:  Vadivel Ganapathy; Muthusamy Thangaraju; Puttur D Prasad
Journal:  Pharmacol Ther       Date:  2008-11-01       Impact factor: 12.310

7.  Pilot study of the utility of the synthetic PET amino-acid radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions.

Authors:  Rianot Amzat; Pooneh Taleghani; Daniel L Miller; Jonathan J Beitler; Leah M Bellamy; Jonathon A Nye; Weiping Yu; Bital Savir-Baruch; Adeboye O Osunkoya; Zhengjia Chen; William F Auffermann; Mark M Goodman; David M Schuster
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

8.  Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis.

Authors:  Baris Turkbey; Esther Mena; Joanna Shih; Peter A Pinto; Maria J Merino; Maria L Lindenberg; Marcelino Bernardo; Yolanda L McKinney; Stephen Adler; Rikard Owenius; Peter L Choyke; Karen A Kurdziel
Journal:  Radiology       Date:  2013-11-08       Impact factor: 11.105

9.  Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis.

Authors:  Jonathan McConathy; Ronald J Voll; Weiping Yu; Ronald J Crowe; Mark M Goodman
Journal:  Appl Radiat Isot       Date:  2003-06       Impact factor: 1.513

10.  Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans.

Authors:  Jonathon A Nye; David M Schuster; Weiping Yu; Vernon M Camp; Mark M Goodman; John R Votaw
Journal:  J Nucl Med       Date:  2007-05-15       Impact factor: 10.057

View more
  37 in total

Review 1.  Anatomic and Molecular Imaging in Prostate Cancer.

Authors:  Eric T Miller; Amirali Salmasi; Robert E Reiter
Journal:  Cold Spring Harb Perspect Med       Date:  2018-03-01       Impact factor: 6.915

Review 2.  PET Tracers Beyond FDG in Prostate Cancer.

Authors:  David M Schuster; Cristina Nanni; Stefano Fanti
Journal:  Semin Nucl Med       Date:  2016-09-07       Impact factor: 4.446

3.  Clinical recommendations in the management of advanced prostate cancer: International Gastrointestinal, Liver and Uro-oncology (IGILUC 2019) experts.

Authors:  Hesham Elghazaly; Nicolas Mottet; Jorge Garcia; Stephane Oudard; Mack Roach; Claude Abbou; Axel Merseburger; Amr Emara; Samir Shehata; Hesham Tawfik; Ola Khorshid; Ahmed Selim; Akram Assem; Khalid Abdelkarim; Lobna Ezz El-Arab; Shouki Bazarbashi; Abbass Omar; Hesham Elwakil; Mohamed Elashry; Mohamed Abou ElFotouh; Tarek Osman; Mai Ezz El Din
Journal:  World J Urol       Date:  2020-07-08       Impact factor: 4.226

Review 4.  Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET.

Authors:  Phillip J Koo; Jennifer J Kwak; Sajal Pokharel; Peter L Choyke
Journal:  Curr Oncol Rep       Date:  2015-12       Impact factor: 5.075

5.  [18F]Fluciclovine PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging-version 1.0.

Authors:  Cristina Nanni; Lucia Zanoni; Tore Bach-Gansmo; Heikki Minn; Frode Willoch; Trond Velde Bogsrud; Ephraim Parent Edward; Bital Savir-Baruch; Eugene Teoh; Fenton Ingram; Stefano Fanti; David M Schuster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-11       Impact factor: 9.236

6.  A PET/MRI study towards finding the optimal [18F]Fluciclovine PET protocol for detection and characterisation of primary prostate cancer.

Authors:  Mattijs Elschot; Kirsten M Selnæs; Elise Sandsmark; Brage Krüger-Stokke; Øystein Størkersen; May-Britt Tessem; Siver A Moestue; Helena Bertilsson; Tone F Bathen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-11-05       Impact factor: 9.236

7.  (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.

Authors:  Cristina Nanni; Lucia Zanoni; Cristian Pultrone; Riccardo Schiavina; Eugenio Brunocilla; Filippo Lodi; Claudio Malizia; Matteo Ferrari; Patrizio Rigatti; Cristina Fonti; Giuseppe Martorana; Stefano Fanti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-10       Impact factor: 9.236

Review 8.  Management of Incidental Breast Lesions Detected at Nuclear Medicine Examinations.

Authors:  W Tania Rahman; Colleen H Neal; Alexis Virginia Nees; Richard K J Brown
Journal:  Radiol Imaging Cancer       Date:  2020-03-20

9.  Selective modification of fluciclovine (18F) transport in prostate carcinoma xenografts.

Authors:  F I Tade; W G Wiles; G Lu; B Bilir; O Akin-Akintayo; J S Lee; D Patil; W Yu; C Ormenisan Gherasim; B Fei; C S Moreno; A O Osunkoya; E J Teoh; S Oka; H Okudaira; M M Goodman; D M Schuster
Journal:  Amino Acids       Date:  2018-06-15       Impact factor: 3.520

10.  Performance of 18F-fluciclovine PET/MR in the evaluation of osseous metastases from castration-resistant prostate cancer.

Authors:  Barbara J Amorim; Vinay Prabhu; Sara S Marco; Debra Gervais; Willian E Palmer; Pedram Heidari; Mark Vangel; Philip J Saylor; Onofrio A Catalano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-06       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.